Breakthrough SUmmit Vinod Khosla's AI medicine prediction
SARAH GONZALEZ FOR STAT
Venture capitalist Vinod Khosla is famous for predictions that have helped usher in the high tech world we live in today — and made him very wealthy in the process. On Wednesday, he made another bold forecast: A fully computerized doctor could be seeing patients before the decade is out.
"Within 5 to 6 years, the FDA will approve a primary care app qualified to practice medicine like your primary care physician," he said at the STAT Breakthrough Summit.
Khosla's prediction comes amid brimming hype around the potential of AI to improve health care. Though there has been a flood of recent scientific papers weighing in on the potential of generative AI, Khosla has for years argued that health care will be transformed by technology. Perhaps his most famous speculations on the subject came in a 2016 paper titled "20 Percent Doctor Included," which predicted 80% of what doctors do could be replaced by tech.
Read more insights from his talk with STAT executive editor Rick Berke.
Artificial intelligence
Why a chatbot might seem more empathetic than a doctor
A recent article in JAMA Internal Medicine compared physician responses to patient questions to those of an AI chatbot and found that the bot was perceived as more empathetic. It prompted a horrified response from many in the field. But as physician Jennifer Lycette writes in a STAT First Opinion, much of the reaction hasn't focused on what may be at the core of issue: Physicians aren't given time to write responses.
"We steal little bits of time throughout the day — five minutes between patients here, three minutes between patients there, and during our 'lunch hour,'" she writes. "In my 17 years in clinical practice, I haven't eaten a lunch away from my desk (unless it was for a required meeting), clicking and typing between harried bites." Read more here.
Digital Therapeutics
Akili posts adult study data
Akili Interactive is coming for adult treatment now. The company, which in 2020 earned FDA clearance for its video game that treats ADHD in kids, just published top-line data suggesting the game improves attention in adults, too.
The adult trial, called STARS-ADHD-Adult, tested six weeks of use of EndeavorRx in 221 adults, 153 of which completed the final assessments. Strikingly, the company reported that the improvement from baseline on a computer-based test of attention was double what was seen in a recent pivotal study in adolescents, and nearly seven times as large as changes seen in kids.
But more analysis still needs to be done on the data to better understand how factors like engagement and demographics may have driven the large effects observed.
"Is it younger people versus older people? Is it women versus men?" Akili chief medical officer Scott Kollins told me. "We would like to understand if there are people who respond really well, or people who respond really poorly so that we can just guide health care providers and patients themselves a little bit more effectively."
Akili's now evaluating its options to get the adult treatment cleared by the FDA as quickly as possible. Read more here.
digital therapeutics
New schizophrenia RCT kicks off
Click Therapeutics and Boehringer Ingelheim this week posted a Phase III clinical trial for a schizophrenia digital therapeutic they're developing. The digital treatment is an adjunct to standard of care medication and is designed to address the negative symptoms of schizophrenia, like withdrawal from others, decreased motivation, and reduced experience of pleasure. The new 432 person trial randomizes patients to one of two schizophrenia digital therapeutics and is designed to be suitable for FDA clearance.
The companies have been testing a candidate called CT-155 for several years, and though they haven't shared data yet, the new trial would seem to suggest that the progress is on track. Another sign: The companies in December announced they were expanding their partnership in a deal that could be worth $460 million plus royalties to Click depending on meeting milestones.
Telehealth DEA to delay telehealth restrictions for Adderall and other drugs
The Drug Enforcement Agency announced Wednesday that it will temporarily extend its Covid-19 emergency telehealth policies, so that doctors can continue prescribing some controlled substances including buprenorphine, which is used to treat opioid addiction, and Adderall, which is used to treat ADHD.
"We recognize the importance of telemedicine in providing Americans with access to needed medications, and we have decided to extend the current flexibilities while we work to find a way forward to give Americans that access with appropriate safeguards," Anne Milgram, the DEA administrator, said in a statement. Read more here.
No comments